Literature DB >> 1981107

Schizophrenia: a subcortical neurotransmitter imbalance syndrome?

M Carlsson1, A Carlsson.   

Abstract

Recent animal experiments suggest that glutamate plays a fundamental role in the control of psychomotor activity. This is illustrated by the finding that even in the virtually complete absence of dopamine, a marked behavioral activation is produced in mice following suppression of glutamatergic neurotransmission. This article discusses the possibility that a deficient activity within the cortico-striatal glutamatergic pathway is an important pathophysiological component in some cases of schizophrenia and that glutamatergic agonists may prove beneficial in this disorder. In a broader perspective, schizophrenia may be looked upon as a syndrome induced by a neurotransmitter imbalance in a feedback-regulated system, where dopamine and glutamate play a crucial role in controlling arousal and the processing of signals from the outer world to the cerebral cortex via the thalamus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981107     DOI: 10.1093/schbul/16.3.425

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  61 in total

Review 1.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

2.  Neurofunctional model of large-scale correlates of selective attention governed by stimulus-novelty.

Authors:  Lars Haab; Carlos Trenado; Mai Mariam; Daniel J Strauss
Journal:  Cogn Neurodyn       Date:  2011-01-15       Impact factor: 5.082

Review 3.  Toward a neurobiology of delusions.

Authors:  P R Corlett; J R Taylor; X-J Wang; P C Fletcher; J H Krystal
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685

4.  Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

Review 5.  Testing models of thalamic dysfunction in schizophrenia using neuroimaging.

Authors:  K Sim; T Cullen; D Ongur; S Heckers
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

6.  Differences in 5-HT2A and mGlu2 Receptor Expression Levels and Repressive Epigenetic Modifications at the 5-HT2A Promoter Region in the Roman Low- (RLA-I) and High- (RHA-I) Avoidance Rat Strains.

Authors:  Luna Fomsgaard; Jose L Moreno; Mario de la Fuente Revenga; Tomasz Brudek; Dea Adamsen; Cristobal Rio-Alamos; Justin Saunders; Anders Bue Klein; Ignasi Oliveras; Toni Cañete; Gloria Blazquez; Adolf Tobeña; Albert Fernandez-Teruel; Javier Gonzalez-Maeso; Susana Aznar
Journal:  Mol Neurobiol       Date:  2017-03-06       Impact factor: 5.590

7.  Pupillometric measures of attentional allocation to target and mask processing on the backward masking task in schizophrenia.

Authors:  Eric Granholm; Scott C Fish; Steven P Verney
Journal:  Psychophysiology       Date:  2009-05       Impact factor: 4.016

Review 8.  Physical Exercise Alleviates Health Defects, Symptoms, and Biomarkers in Schizophrenia Spectrum Disorder.

Authors:  Trevor Archer; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-07-15       Impact factor: 3.911

Review 9.  [Why do schizophrenic patients smoke?].

Authors:  K Cattapan-Ludewig; S Ludewig; E Jaquenoud Sirot; M Etzensberger; F Hasler
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

10.  Clinical correlates of thalamus volume deficits in anti-psychotic-naïve schizophrenia patients: A 3-Tesla MRI study.

Authors:  Naren P Rao; Sunil Kalmady; Rashmi Arasappa; Ganesan Venkatasubramanian
Journal:  Indian J Psychiatry       Date:  2010-07       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.